Intellectus Partners LLC Takes $70,000 Position in Immatics (NASDAQ:IMTX)

Intellectus Partners LLC bought a new stake in Immatics (NASDAQ:IMTX) during the first quarter, Holdings Channel reports. The institutional investor bought 15,500 shares of the company’s stock, valued at approximately $70,000.

A number of other institutional investors have also modified their holdings of IMTX. Suvretta Capital Management LLC acquired a new stake in Immatics during the 4th quarter worth $36,014,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immatics by 43.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company’s stock valued at $75,400,000 after buying an additional 3,225,141 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Immatics by 67.3% during the fourth quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company’s stock worth $44,615,000 after buying an additional 2,525,000 shares during the period. Braidwell LP boosted its stake in shares of Immatics by 112.7% during the fourth quarter. Braidwell LP now owns 3,503,965 shares of the company’s stock worth $24,913,000 after buying an additional 1,856,400 shares during the period. Finally, Paradigm Biocapital Advisors LP grew its holdings in shares of Immatics by 38.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company’s stock worth $38,496,000 after buying an additional 1,509,547 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Immatics Stock Performance

IMTX stock opened at $5.97 on Friday. Immatics has a one year low of $3.30 and a one year high of $13.70. The stock has a market capitalization of $725.65 million, a PE ratio of -9.05 and a beta of 0.83. The company has a fifty day moving average of $4.68 and a 200-day moving average of $5.52.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. The firm had revenue of $20.12 million during the quarter, compared to analysts’ expectations of $14.92 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Equities analysts forecast that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IMTX shares. Deutsche Bank Aktiengesellschaft initiated coverage on Immatics in a research report on Wednesday, May 28th. They issued a “buy” rating and a $10.00 price target on the stock. Wall Street Zen downgraded Immatics from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.